Roche

Roche secures rights to South Korean experimental obesity treatment

Roche subsidiary Genentech has secured worldwide rights, outside South Korea, to develop and market Hanmi Pharmaceutical’s experimental obesity treatment HM17321. The agreement could be worth up to $2.3 billion, although the drug remains in early-stage clinical trials.